BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim Y, Chang Y, Cho YK, Ahn J, Shin H, Ryu S. Obesity and Weight Gain Are Associated With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2019;17:543-550.e2. [PMID: 30012432 DOI: 10.1016/j.cgh.2018.07.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Ng CH, Lin SY, Chin YH, Lee MH, Syn N, Goh XL, Koh JH, Quek J, Hao Tan DJ, Mok SF, Tan E, Dan YY, Chew N, Khoo CM, Siddiqui MS, Muthiah M. Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials. Endocr Pract 2021:S1530-891X(21)01244-1. [PMID: 34606980 DOI: 10.1016/j.eprac.2021.09.013] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 McHenry S, Tirath A, Tsai R, Sharma Y, Flores AG, Davidson NO, Fowler KJ, Ciorba MA, Deepak P. Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic Fatty Liver Disease in Patients With Crohn's Disease. Inflamm Bowel Dis 2020;26:1917-25. [PMID: 31907542 DOI: 10.1093/ibd/izz324] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Hanai T, Shiraki M, Imai K, Suetsugu A, Takai K, Shimizu M. Late Evening Snack with Branched-Chain Amino Acids Supplementation Improves Survival in Patients with Cirrhosis. J Clin Med 2020;9:E1013. [PMID: 32260139 DOI: 10.3390/jcm9041013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Chou Y, Sun Z, Shen W, Yang Y, Lu F, Chang C, Li C, Wu J. Cumulative Betel Quid Chewing and the Risk of Significant Liver Fibrosis in Subjects With and Without Metabolic Syndrome. Front Nutr 2022;9:765206. [DOI: 10.3389/fnut.2022.765206] [Reference Citation Analysis]
5 Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than TA, Abdelmalek MF, Suzuki A. Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. Hepatology. 2019;70:1457-1469. [PMID: 30924946 DOI: 10.1002/hep.30626] [Cited by in Crossref: 163] [Cited by in F6Publishing: 160] [Article Influence: 54.3] [Reference Citation Analysis]
6 Liu D, Shen Y, Zhang R, Xun J, Wang J, Liu L, Steinhart C, Chen J, Lu H. Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China. J Gastroenterol Hepatol 2021;36:1670-8. [PMID: 33140878 DOI: 10.1111/jgh.15320] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Zhu B, Chan SL, Li J, Li K, Wu H, Cui K, Chen H. Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment. Front Cardiovasc Med 2021;8:742382. [PMID: 34557535 DOI: 10.3389/fcvm.2021.742382] [Reference Citation Analysis]
8 Koo DJ, Lee MY, Jung I, Moon SJ, Kwon H, Park SE, Rhee EJ, Lee WY. Changes in Insulin Resistance Index and the Risk of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease without Diabetes: Kangbuk Samsung Health Study. Endocrinol Metab (Seoul) 2021;36:1016-28. [PMID: 34674510 DOI: 10.3803/EnM.2021.1110] [Reference Citation Analysis]
9 Natarajan Y, Kramer JR, Yu X, Li L, Thrift AP, El-Serag HB, Kanwal F. Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes. Hepatology 2020;72:1242-52. [PMID: 32022277 DOI: 10.1002/hep.31157] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
10 Jang EH, Chang Y, Ryu S, Kim S, Kim YH, Sung KC, Cho YK, Lee SJ, Shin H, Wild SH, Byrne CD. Cardiovascular Health Metrics in the Development and Regression of Nonalcoholic Fatty Liver Disease: A Cohort Study. J Clin Med 2019;8:E610. [PMID: 31064105 DOI: 10.3390/jcm8050610] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Bajaj HS, Burrows M, Blavignac J, Paron E, Camacho F, Gould E, Barakat M. Extended‐release naltrexone/bupropion and liver health: Pooled, post hoc analysis from four randomized controlled trials. Diabetes Obes Metab 2021;23:861-5. [DOI: 10.1111/dom.14284] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Patton H, Heimbach J, McCullough A. AGA Clinical Practice Update on Bariatric Surgery in Cirrhosis: Expert Review. Clin Gastroenterol Hepatol 2021;19:436-45. [PMID: 33393473 DOI: 10.1016/j.cgh.2020.10.034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Spagnuolo R, Montalcini T, De Bonis D, Ferro Y, Cosco C, Mazza E, Romeo S, Doldo P, Pujia A. Weight Gain and Liver Steatosis in Patients with Inflammatory Bowel Diseases. Nutrients 2019;11:E303. [PMID: 30717085 DOI: 10.3390/nu11020303] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
14 Wirth KM, Sheka AC, Kizy S, Irey R, Benner A, Sieger G, Simon G, Ma S, Lake J, Aliferis C, Leslie D, Marmor S, Ikramuddin S. Bariatric Surgery is Associated With Decreased Progression of Nonalcoholic Fatty Liver Disease to Cirrhosis: A Retrospective Cohort Analysis. Ann Surg 2020;272:32-9. [PMID: 32224733 DOI: 10.1097/SLA.0000000000003871] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
15 Simon TG, Kim MN, Luo X, Yang W, Ma Y, Chong DQ, Fuchs CS, Meyerhardt JA, Corey KE, Chung RT, Stampfer M, Zhang X, Giovannucci EL, Chan AT. Physical activity compared to adiposity and risk of liver-related mortality: Results from two prospective, nationwide cohorts. J Hepatol 2020;72:1062-9. [PMID: 31954204 DOI: 10.1016/j.jhep.2019.12.022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
16 Koutoukidis DA, Koshiaris C, Henry JA, Noreik M, Morris E, Manoharan I, Tudor K, Bodenham E, Dunnigan A, Jebb SA, Aveyard P. The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: A systematic review and meta-analysis. Metabolism 2021;115:154455. [PMID: 33259835 DOI: 10.1016/j.metabol.2020.154455] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
17 Vieira Barbosa J, Lai M. Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting. Hepatol Commun 2021;5:158-67. [PMID: 33553966 DOI: 10.1002/hep4.1618] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
18 Chou YT, Li CH, Sun ZJ, Shen WC, Yang YC, Lu FH, Chang CJ, Wu JS. A Positive Relationship between Betel Nut Chewing and Significant Liver Fibrosis in NAFLD Subjects, but Not in Non-NAFLD Ones. Nutrients 2021;13:914. [PMID: 33799865 DOI: 10.3390/nu13030914] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Jung CH, Rhee EJ, Kwon H, Chang Y, Ryu S, Lee WY. Visceral-to-Subcutaneous Abdominal Fat Ratio Is Associated with Nonalcoholic Fatty Liver Disease and Liver Fibrosis. Endocrinol Metab (Seoul) 2020;35:165-76. [PMID: 32207277 DOI: 10.3803/EnM.2020.35.1.165] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
20 McHenry S, Park Y, Browning JD, Sayuk G, Davidson NO. Dallas Steatosis Index Identifies Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2020;18:2073-2080.e7. [PMID: 31982611 DOI: 10.1016/j.cgh.2020.01.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
21 Kim Y, Chang Y, Cho YK, Ahn J, Shin H, Ryu S. Metabolically healthy versus unhealthy obesity and risk of fibrosis progression in non‐alcoholic fatty liver disease. Liver Int 2019;39:1884-94. [DOI: 10.1111/liv.14184] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
22 Pellicori P, Vaduganathan M, Ferreira JP, Zannad F, Sanyal AJ. Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: Implications for future trial design. Diabetes Metab 2021;:101281. [PMID: 34543735 DOI: 10.1016/j.diabet.2021.101281] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Kawaguchi T, Tsutsumi T, Nakano D, Torimura T. MAFLD: Renovation of clinical practice and disease awareness of fatty liver. Hepatol Res 2021. [PMID: 34472683 DOI: 10.1111/hepr.13706] [Reference Citation Analysis]
24 Koo DJ, Lee MY, Jung I, Moon SJ, Kwon H, Park SE, Rhee EJ, Lee WY. Baseline homeostasis model assessment of insulin resistance associated with fibrosis progression in patients with nonalcoholic fatty liver disease without diabetes: A cohort study. PLoS One 2021;16:e0255535. [PMID: 34432804 DOI: 10.1371/journal.pone.0255535] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]